PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
A major new review published in Critical Reviews in Food Science and Nutrition has looked at common beliefs about how much protein people need and the health benefits it provides. The study, titled Examining Widely Held Propositions on Human Dietary Protein Needs and Benefits, was based on an international...
The U.S. Food and Drug Administration has added bemotrizinol to the list of permitted sunscreen active ingredients, marking a significant milestone in the agency's efforts to advance sunscreen innovation. Bemotrizinol is the first new active ingredient added to the over-the-counter sunscreen monograph...
Seed Junky Genetics, known for its cannabis genetics and intellectual property, is breaking into the European medical cannabis scene, teaming up with Green Success Group to kick off operations in Germany and the UK.
Johnson & Johnson (JNJ) reported that its IMAAVY (nipocalimab-aahu) delivered a rapid and durable improvement in hemoglobin levels in patients with warm autoimmune hemolytic anemia (wAIHA), marking a significant step forward for a rare autoimmune disease with no FDA-approved treatments